Adding IVCF To Fondaparinux Does Not Benefit Cancer Patients With Blood Clots
7/08/2011
Cancer patients with blood clots - which occur in one of every 200 cancer patients and are the second most common cause of death among cancer patients - gain no benefit from the insertion of an inferior vena cava filter (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research presented at the 14th World Conference on Lung Cancer, hosted by the Intern...
Large State Disparities In Progress Against Colorectal Cancer, Report Reveals
7/08/2011
Progress in reducing colorectal cancer (CRC) mortality rates varies significantly across states, with rates in the Northeast showing the most progress and those in the South showing the least progress, according to a new study. As a result, the highest burden of CRC mortality shifted from the Northeast in the early 1990s to the southern states along the Appalachian corridor in the mid 2000s...
Southern U.S. States Lag In Reducing Death Rates From Colorectal Cancer
7/08/2011
Improvements in colorectal cancer mortality rates are concentrated in the northern part of the United States, while southern states continue to fall behind, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. Ahmedin Jemal, D.V.M., Ph.D...
Targeting Stem Cells To Combat Deadly Brain Cancer
7/08/2011
Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer. In the July 8th issue of the journal Cell, a Cell Press publication, a new study identifies an enzyme found in glioma stem cells that allows them to grow and seed tumors. Importantly, normal stem cells, including those in the brain, don't appear to share that same dependency...
Cancer In The Elderly
7/08/2011
In many American families, including those from minority populations, people from a wide range of ages live together under the same roof. The elder folk in these homes face what are called the diseases of aging, including hypertension, diabetes, arthritis, and cancer. Cancer is a common event among older people, and as we age the risk increases, even if no one in our family has had the disease...
Half-Matched Transplants Widen Pool Of Donors For Leukemia And Lymphoma
7/08/2011
Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy...
Ching-Hon Pui, M.D., an eminent leader in the research and treatment of pediatric leukemia at St. Jude Children's Research Hospital, has been named the recipient of the 2011 Henry M. Stratton Medal from the American Society of Hematology (ASH). The award recognizes the progress Pui has made in the fight against this blood cancer during the past three decades...
Pathway Activation Discovery Could Lead To New Cancer Drugs
7/08/2011
A discovery by University of Alabama at Birmingham researchers about a how a common cell pathway that helps regulate cell survival and production is turned on could lead to new treatments for autoimmune diseases and cancer. The study, published in the July 2011 issue of the journal Blood, details for the first time how the JAK-STAT pathway is activated by the protein CK2...
Scripps Research Scientists Find 'Brake-Override' Proteins That Enable Development Of Some Cancers
7/08/2011
Scripps Research Institute scientists have discovered a basic mechanism that can enable developing cancer cells to sustain abnormal growth. The finding is expected to lead to the targeting of this mechanism with drugs and diagnostic techniques...
Charité Establishes NanoTherm® Therapy For The Treatment Of Recurrent Brain Tumors
7/08/2011
Universitätsmedizin Berlin has established a new treatment at the Clinic for Radiooncology, Campus Virchow, which offers selected patients a nanomedicine approach for the treatment of recurrent brain tumors. Researchers at Charité developed the scientific basis for the nanotechnology-based cancer therapy...